Medical devices, healthcare technology and the business of care
510(k) clearance · K260686

Zylox PanFlex Percutaneous Transluminal Angioplasty Scoring Catheter

Zylox Medtech Co., Ltd. · Decision date Oct 22, 2026

MEDTECHLEDGER EXPLANATIONK260686

What did the FDA decide?

The FDA recorded a substantial equivalence determination, decision code SESE, on October 22, 2026 for the Zylox PanFlex Percutaneous Transluminal Angioplasty Scoring Catheter, submitted by Zylox Medtech Co., Ltd. under section 510(k) premarket notification K260686. The device is listed under product code PNO with a Cardiovascular specialty. The decision letter addresses Siran Wu as regulatory affairs specialist and states that the device is substantially equivalent to legally marketed predicate devices for the indications for use given in the enclosure.

SESE denotes 510(k) clearance rather than premarket approval, so the record covers a finding of substantial equivalence, not a new PMA. The source data do not include the indications for use, the predicate devices named, or any component-level description of the scoring catheter, so the specific design and labeled use remain unknown from this record. No clinical or efficacy conclusions are drawn here.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Cardiovascular
Decision date
Oct 22, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K260686
Regulatory pathway
510(k) premarket notification
Product code
PNO
Decision code
SESE
Decision date
Oct 22, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Catheter, Percutaneous, Cutting/Scoring.

Product code
PNO
FDA device class
2

FDA decision timeline

  1. K260686 received

    Application receipt date recorded by FDA.

  2. K260686 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code PNO

Product / regulatory recordCompanyPathwayDecision dateSource
OrbusNeich Medical (Shenzhen) Co., Ltd.510(k) clearanceSep 16, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Zylox Medtech Co., Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Hangzhou

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records